Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Vega-Hernandez, G.
4061  Ergebnisse:
Personensuche X
?
1

P072 Real-world impact of elexacaftor/tezacaftor/ivacaftor ..:

Cipolli, M. ; Vega-Hernandez, G. ; Fratoni, A....
Journal of Cystic Fibrosis.  23 (2024)  - p. S89 , 2024
Link: https://doi.org/10.1016/..
 
?
2

EPS10.08 LONGITUDE: an observational study of the long-term..:

Vega-Hernandez, G. ; Adams, F. ; Wilfin, A....
Journal of Cystic Fibrosis.  23 (2024)  - p. S65 , 2024
Link: https://doi.org/10.1016/..
 
?
3

P117 A longitudinal study on the impact of elexacaftor/teza..:

Sutharsan, S. ; Mondéjar-Lopez, P. ; Duckers, J....
Journal of Cystic Fibrosis.  22 (2023)  - p. S99-S100 , 2023
Link: https://doi.org/10.1016/..
 
?
4

P118 Real-world impact of elexacaftor/tezacaftor/ivacaftor ..:

Thia, L.P. ; Thursfield, R. ; Lee, T....
Journal of Cystic Fibrosis.  22 (2023)  - p. S100 , 2023
Link: https://doi.org/10.1016/..
 
?
5

EE182 CFTR-Modulators (CFTRM) Impact on Real-World Healthca..:

Vega-Hernandez, G. ; Duran, A. ; Akbari, A...
Value in Health.  26 (2023)  6 - p. S92 , 2023
Link: https://doi.org/10.1016/..
 
?
6

MSR6 Modeling Survival of People with Cystic Fibrosis (PWCF..:

Pedra, G ; Daly, C ; Pinto, LA...
Value in Health.  25 (2022)  7 - p. S518 , 2022
Link: https://doi.org/10.1016/..
 
?
7

PRS2 Modelling Survival of People with Cystic Fibrosis (PWC..:

Vega-Hernandez, G. ; MacGregor, G. ; Lopez, A...
Value in Health.  24 (2021)  - p. S213 , 2021
Link: https://doi.org/10.1016/..
 
?
8

PRS31 Modelling Survival of People with Cystic Fibrosis (PW..:

Vega-Hernandez, G. ; MacGregor, G. ; Lopez, A...
Value in Health.  24 (2021)  - p. S218 , 2021
Link: https://doi.org/10.1016/..
 
?
9

Assessing Patient Preference for Insulin Intensification in..:

Vega-Hernandez, G ; Bogelund, M
Value in Health.  19 (2016)  7 - p. A677 , 2016
Link: https://doi.org/10.1016/..
 
?
10

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for ..:

Schlueter, M ; Vega-Hernandez, G ; Wojcik, R
Value in Health.  19 (2016)  7 - p. A675 , 2016
Link: https://doi.org/10.1016/..
 
?
11

Liraglutide Versus Dapagliflozin for the Treatment of Patie..:

Ramírez de Arellano Serna, A ; Mezquita-Raya, P ; Vega-Hernandez, G..
Value in Health.  19 (2016)  7 - p. A674 , 2016
Link: https://doi.org/10.1016/..
 
?
12

Barriers to Intensification of Insulin Treatment In Patient..:

Bøgelund, M ; Vega-Hernandez, G ; Lopes, S.
Value in Health.  18 (2015)  7 - p. A612 , 2015
Link: https://doi.org/10.1016/..
 
?
13

Patient Perspective on Convenience and Intensification of I..:

Bøgelund, M ; Vega-Hernandez, G ; Nicoziani, P.
Value in Health.  18 (2015)  7 - p. A612-A613 , 2015
Link: https://doi.org/10.1016/..
 
?
14

Potential Barriers to Insulin Intensification Among Patient..:

Bøgelund, M ; Vega-Hernandez, G ; Seitz, L.
Value in Health.  18 (2015)  7 - p. A612 , 2015
Link: https://doi.org/10.1016/..
 
?
15

Direct Medical Costs of Treating Diabetes-Related Complicat..:

Elgart, J. ; De la Llave, G. ; Camillucci, C....
Value in Health.  16 (2013)  7 - p. A688 , 2013
Link: https://doi.org/10.1016/..
 
1-15